The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors
Abstract
Adaptation to hypoxia is critical for survival and regulates multiple processes, including erythropoiesis and vasculogenesis. Chuvash polycythemia is a hypoxia-sensing disorder characterized by homozygous mutation (598C>T) of von Hippel-Lindau gene (VHL), a negative regulator of hypoxia sensing. Although endemic to the Chuvash population of Russia, this mutation occurs worldwide and originates from a single ancient event. That VHL 598C>T homozygosity causes elevated normoxic levels of the transcription factor hypoxia inducible factor-1α (HIF-1α), serum erythropoietin and hemoglobin is known, but the disease phenotype has not been documented in a controlled manner. In this matched cohort study, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum vascular endothelial growth factor (VEGF) concentrations (P < .0005), as well as premature mortality related to cerebral vascular events and peripheral thrombosis. Spinocerebellar hemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL syndrome were not found, suggesting that overexpression of HIF-1α and VEGF is not sufficient for tumorigenesis. Although hemoglobin-adjusted serum erythropoietin concentrations were approximately 10-fold higher in VHL 598C>T homozygotes than in controls, erythropoietin response to hypoxia was identical. Thus, Chuvash polycythemia is a distinct VHL syndrome manifested by thrombosis, vascular abnormalities, and intact hypoxic regulation despite increased basal expression of hypoxia-regulated genes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To explain the observed suppression of hepcidin, we considered the possibility that testosterone suppresses the cytokine interleukin-6, a known positive regulator of hepcidin (23).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [23]
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Lonser, R. R., Glenn, G. M., Walther, M. M., Chew, E. Y., Libutti, S. K., Linehan, W. M., & Oldfield, E. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13643-4 · Cited by 1,630
Nitric oxide synthases: which, where, how, and why?
Michel, T. M., & Féron, O. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119750 · Cited by 1,024
Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology
Semenza, G. L. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02090-1 · Cited by 930
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Erythropoietin: Physiology and Pharmacology Update
Fisher, J. W. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800101 · Cited by 707
VEGF Gene Delivery to Myocardium
Lee, R. J., Springer, M. L., Blanco-Bose, W. E., Shaw, R. M., Ursell, P. C., & Blau, H. M. (2000) · Circulation · doi:10.1161/01.cir.102.8.898 · Cited by 696
Diagnosis and classification of the polycythemias.
Berlin, N. I. (1975) · PubMed · Cited by 557
Declerck, P. J., Alessi, M., Verstreken, M. F. K., Kruithof, E. K. O., Juhan-Vague, I., & Collen, D. (1988) · Blood · doi:10.1182/blood.v71.1.220.220 · Cited by 537
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
Ang, S. O., Chen, H., Hirota, K., Gordeuk, V. R., Jelinek, J., Guan, Y., Liu, E., Sergueeva, A. I., Miasnikova, G. Y., Mole, D., et al. (2002) · Nature Genetics · doi:10.1038/ng1019 · Cited by 510
Self-citation
Research works printed but not linked: 1
- Jaakola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel Lindau ubiqutiylation complex by O2-regulated hydroxylation. Science. 2001;292: 48-72.
Cited by
Sorted by citations
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Jones, M., Ibels, L. S., Schenkel, B., & Zagari, M. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 1,812
Beall, C. M., Cavalleri, G. L., Deng, L., Elston, R. C., Gao, Y., Knight, J., Li, C., Li, J. C., Liang, Y., McCormack, M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002443107 · Cited by 845
Regulation of erythropoiesis by hypoxia-inducible factors
Haase, V. H. (2013) · Blood Reviews · doi:10.1016/j.blre.2012.12.003 · Cited by 787
von Hippel–Lindau disease: A clinical and scientific review
Maher, E. R., Neumann, H. P. H., & Richard, S. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.175 · Cited by 749
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
Peyssonnaux, C., Zinkernagel, A. S., Schuepbach, R. A., Rankin, E., Vaulont, S., Haase, V. H., Nizet, V., & Johnson, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31370 · Cited by 639
The stimulation of thrombosis by hypoxia
Gupta, N., Zhao, Y., & Evans, C. E. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.07.013 · Cited by 455
Bachman, E., Travison, T. G., Basaria, S., Davda, M. N., Guo, W., Li, M., Connor Westfall, J., Bae, H., Gordeuk, V., & Bhasin, S. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt154 · Cited by 426
Self-citationHypoxic regulation of erythropoiesis and iron metabolism
Haase, V. H. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00174.2010 · Cited by 347
Kaelin, W. G. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 349
Hypoxia-inducible factors in the kidney
Haase, V. H. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00071.2006 · Cited by 334
Percy, M. J., Zhao, Q., Flores, A., Harrison, C., Lappin, T. R. J., Maxwell, P. H., McMullin, M. F., & Lee, F. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508423103 · Cited by 330
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease
Fraisl, P., Aragonés, J., & Carmeliet, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2761 · Cited by 326
Genetic analysis of von Hippel-Lindau disease
Nordstrom-O'Brien, M., van der Luijt, R. B., van Rooijen, E., van den Ouweland, A. M., Majoor‐Krakauer, D. F., Lolkema, M. P., van Brussel, A. S. A., Voest, E. E., & Giles, R. H. (2010) · Human Mutation · doi:10.1002/humu.21219 · Cited by 322
Pathogenesis of primary varicose veins
Lim, C. S., & Davies, A. H. (2009) · British journal of surgery · doi:10.1002/bjs.6798 · Cited by 295
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure
Minamishima, Y. A., Moslehi, J., Bardeesy, N., Cullen, D., Bronson, R. T., & Kaelin, W. G. (2008) · Blood · doi:10.1182/blood-2007-10-117812 · Cited by 294
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
Maxwell, P. H., & Eckardt, K. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.193 · Cited by 288
The human side of hypoxia‐inducible factor
Smith, T. G., Robbins, P. A., & Ratcliffe, P. J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07029.x · Cited by 270
Genotype-phenotype correlations in von Hippel-Lindau disease
Ong, K. R., Woodward, E. R., Killick, P., Lim, C., MacDonald, F., & Maher, E. R. (2006) · Human Mutation · doi:10.1002/humu.20385 · Cited by 255
Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension
Thompson, A. A. R., & Lawrie, A. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.11.005 · Cited by 243
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
Kim, W. Y., Safran, M., Buckley, M. R., Ebert, B. L., Glickman, J., Bosenberg, M., Regan, M., & Kaelin, W. G. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601300 · Cited by 235
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
Kaelin, W. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.165 · Cited by 217
The von Hippel-Lindau Tumor Suppressor Gene
Elias, R. M., Zhang, Q. H., & Brugarolas, J. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000480 · Cited by 210
Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome
Nielsen, S. M., Rhodes, L. V., Blanco, I., Chung, W. K., Eng, C., Maher, E. R., Richard, S., & Giles, R. H. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.6140 · Cited by 187
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Sanghani, N. S., & Haase, V. H. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.04.004 · Cited by 188
Mutation of von Hippel–Lindau Tumour Suppressor and Human Cardiopulmonary Physiology
Smith, T. G., Brooks, J. T., Balanos, G. M., Lappin, T. R., Layton, D. M., Leedham, D. L., Liu, C., Maxwell, P. H., McMullin, M. F., McNamara, C. J., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030290 · Cited by 182
The haematocrit and platelet target in polycythemia vera
Nisio, M. D., Barbui, T., Gennaro, L. D., Borrelli, G., Finazzi, G., Landolfi, R., Leone, G. G. M., Marfisi, R., Porreca, E., Ruggeri, M., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06430.x · Cited by 182
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
Yang, H., Minamishima, Y. A., Yan, Q., Schlisio, S., Ebert, B. L., Zhang, X., Zhang, L., Kim, W. Y., Olumi, A. F., & Kaelin, W. G. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.09.010 · Cited by 182
The HIF pathway and erythrocytosis
Lee, F. S., & Percy, M. J. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130321 · Cited by 177
Flamme, I., Oehme, F., Ellinghaus, P., Jeske, M., Keldenich, J., & Thuß, U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111838 · Cited by 174
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
Colaizzo, D., Amitrano, L., Tiscia, G. L., Scenna, G., Grandone, E., Guardascione, M. A., Brancaccio, V., & Margaglione, M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02277.x · Cited by 168
Haddad, J. J., & Harb, H. L. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.09.029 · Cited by 166
The anaemia of cancer: death by a thousand cuts
Spivak, J. L. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1648 · Cited by 166
HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism
Haase, V. H. (2017) · Hemodialysis International · doi:10.1111/hdi.12567 · Cited by 165
HYPOXIA‐INDUCED ERYTHROPOIETIN PRODUCTION: A PARADIGM FOR OXYGEN‐REGULATED GENE EXPRESSION
Stockmann, C., & Fandrey, J. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04474.x · Cited by 159
Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia
Macdougall, I. C., & Eckardt, K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69120-4 · Cited by 146
van Rooijen, E., Voest, E. E., Logister, I., Korving, J., Schwerte, T., Schulte‐Merker, S., Giles, R. H., & van Eeden, F. J. (2009) · Blood · doi:10.1182/blood-2008-07-167890 · Cited by 146
The von Hippel–Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice
Hickey, M. M., Richardson, T., Wang, T., Mosqueira, M., Arguiri, E., Yu, H. D., Yu, Q., Solomides, C., Morrisey, E. E., Khurana, T. S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36362 · Cited by 143
Kapitsinou, P. P., Rajendran, G., Astleford, L., Michael, M., Schonfeld, M. P., Fields, T. A., Shay, S. D., French, J. L., West, J. D., & Haase, V. H. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.01055-15 · Cited by 134
Cytokines and the regulation of hypoxia-inducible factor (HIF)-1α
Haddad, J. J., & Harb, H. L. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.11.009 · Cited by 139
VHL and Hypoxia Signaling: Beyond HIF in Cancer
Zhang, J., & Zhang, Q. H. (2018) · Biomedicines · doi:10.3390/biomedicines6010035 · Cited by 133
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis
Percy, M. J., Beer, P. A., Campbell, G., Dekker, A. W., Green, A. R., Oscier, D., Rainey, M. G., van Wijk, R., Wood, M., Lappin, T. R. J., et al. (2008) · Blood · doi:10.1182/blood-2008-02-137703 · Cited by 127
The complete evaluation of erythrocytosis: congenital and acquired
Patnaik, M. M., & Tefferi, A. (2009) · Leukemia · doi:10.1038/leu.2009.54 · Cited by 125
Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases
Bento, C., Percy, M. J., Gardie, B., Maia, T. M., van Wijk, R., Perrotta, S., Ragione, F. D., Almeida, H., Rossi, C., Girodon, F., et al. (2013) · Human Mutation · doi:10.1002/humu.22448 · Cited by 131
Erythrocytosis: the HIF pathway in control
Franke, K., Gassmann, M., & Wielockx, B. (2013) · Blood · doi:10.1182/blood-2013-01-478065 · Cited by 117
Heights and haematology: the story of haemoglobin at altitude
Windsor, J. S., & Rodway, G. W. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.049734 · Cited by 112
Hickey, M. M., Lam, J. C., Bezman, N. A., Rathmell, W. K., & Simon, M. C. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32614 · Cited by 110
The effect of erythropoietin on normal and neoplastic cells
Sinclair, A. M., & Elliott (2012) · Biologics · doi:10.2147/btt.s32281 · Cited by 110
Pathophysiology of anemia and erythrocytosis
Hodges, V. M., Rainey, S., Lappin, T. R. J., & Maxwell, A. P. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.006 · Cited by 118
Erythrocytosis and Pulmonary Hypertension in a Mouse Model of Human HIF2A Gain of Function Mutation
Tan, Q., Kerestes, H., Percy, M. J., Pietrofesa, R. A., Chen, L., Khurana, T. S., Christofidou‐Solomidou, M., Lappin, T. R. J., & Lee, F. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444059 · Cited by 104
Congenital polycythemias/erythrocytoses.
Gordeuk, V. R., Stockton, D. W., & Prchal, J. T. (2005) · PubMed · Cited by 105
Self-citationHypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease
Kaplan, J., Sharma, N., & Dikdan, S. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020389 · Cited by 108
Expression and function of erythropoietin receptors in tumors
Sinclair, A. M., Todd, M. D., Forsythe, K., Knox, S. J., Elliott, S., & Begley, C. G. (2007) · Cancer · doi:10.1002/cncr.22832 · Cited by 99
Human disorders of ubiquitination and proteasomal degradation
Jiang, Y., & Beaudet, A. L. (2004) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000133634.79661.cd · Cited by 100
Lenglet, M., Robriquet, F., Schwarz, K., Camps, C., Couturier, A., Hoogewijs, D., Buffet, A., Knight, S. J. L., Gad, S., Couvé, S., et al. (2018) · Blood · doi:10.1182/blood-2018-03-838235 · Cited by 103
Hemangiosarcoma in Rodents: Mode-of-Action Evaluation and Human Relevance
Cohen, S. M., Storer, R. D., Criswell, K. A., Doerrer, N. G., Dellarco, V. L., Pegg, D. G., Wojcinski, Z. W., Malarkey, D. E., Jacobs, A. C., Klaunig, J. E., et al. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp131 · Cited by 97
VHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment
Rathmell, W. K., & Chen, S. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.1.63 · Cited by 96
Perrotta, S., Nobili, B., Ferraro, M., Migliaccio, C., Borriello, A., Cucciolla, V., Martinelli, V., Rossi, F., Punzo, F., Cirillo, P., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2422 · Cited by 93
Formenti, F., Beer, P. A., Croft, Q. P. P., Dorrington, K. L., Gale, D. P., Lappin, T. R. J., Lucas, G. S., Maher, E. R., Maxwell, P. H., McMullin, M. F., et al. (2011) · The FASEB Journal · doi:10.1096/fj.10-177378 · Cited by 92
Yan, L. Y., Colandrea, V. J., & Hale, J. J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.510836 · Cited by 87
Franke, K., Kalucka, J. M., Mamlouk, S., Singh, R. P., Muschter, A., Weidemann, A., Iyengar, V., Jahn, S., Wieczorek, K. S., Geiger, K. D., et al. (2012) · Blood · doi:10.1182/blood-2012-08-449181 · Cited by 86
Gangaraju, R., Song, J., Kim, S. J., Tashi, T., Reeves, B., Sundar, K. M., Thiagarajan, P., & Prchal, J. T. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001379 · Cited by 84
Self-citationSpivak, J. L. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-5-201003020-00008 · Cited by 81
Haase, V. H. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.03.006 · Cited by 82
Systemic VHL gene functions and the VHL disease
Bader, H. L., & Hsu, T. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.032 · Cited by 81
Metabolic aspects of high‐altitude adaptation in Tibetans
Ge, R., Simonson, T. S., Gordeuk, V. R., Prchal, J. T., & McClain, D. A. (2015) · Experimental Physiology · doi:10.1113/ep085292 · Cited by 78
Self-citationBushuev, V. I., Miasnikova, G., Sergueeva, A., Polyakova, L. A., Okhotin, D. J., Gaskin, P. R. A., Debebe, Z., Nekhai, S. A., Castro, O. L., Prchal, J. T., et al. (2006) · PubMed · Cited by 76
Self-citationTherapeutic Manipulation of the HIF Hydroxylases
Nagel, S., Talbot, N. P., Mecinović, J., Smith, T. G., Buchan, A. M., & Schofield, C. J. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2711 · Cited by 77
Turning the Oxygen Dial: Balancing the Highs and Lows
Baik, A. H., & Jain, I. H. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.04.005 · Cited by 70
Raffetto, J. D., & Khalil, R. A. (2021) · Vessel Plus · doi:10.20517/2574-1209.2021.16 · Cited by 80
Biomolecular Mechanisms in Varicose Veins Development
Segiet, O. A., Brzozowa-Zasada, M., Piecuch, A., Dudek, D., Reichman-Warmusz, E., & Wojnicz, R. (2014) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2014.10.009 · Cited by 72
Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis
Gordeuk, V. R., Key, N. S., & Prchal, J. T. (2019) · Haematologica · doi:10.3324/haematol.2018.210732 · Cited by 79
Self-citationSemenza, G. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102602 · Cited by 74
Nakamura, E., de Abreu-e-Lima, P. C., Awakura, Y., Inoue, T., Kamoto, T., Ogawa, O., Kotani, H., Manabe, T., Zhang, G., Kondo, K., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050867 · Cited by 68
Organ Protection by Hypoxia and Hypoxia‐Inducible Factors
Bernhardt, W. M., Warnecke, C., Willam, C., Tanaka, T., Wiesener, M. S., & Eckardt, K. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35012-x · Cited by 70
Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss
Liu, X., Simon, J. M., Xie, H., Hu, L., Wang, J., Zurlo, G., Fan, C., Ptacek, T., Herring, L. E., Tan, X. M., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.009 · Cited by 70
Wu, D., Dasgupta, A., Read, A. D., Bentley, R. E. T., Motamed, M., Chen, K., Al‐Qazazi, R., Mewburn, J. D., Dunham‐Snary, K. J., Alizadeh, E., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.452 · Cited by 69
The Role of Hypoxia in Vascular Injury and Repair
Walshe, T. E., & D'Amore, P. A. (2007) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151501 · Cited by 70
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views
Gangat, N., Szuber, N., Pardanani, A. D., & Tefferi, A. (2021) · Leukemia · doi:10.1038/s41375-021-01290-6 · Cited by 66
Saturation genome editing maps the functional spectrum of pathogenic VHL alleles
Buckley, M., Terwagne, C., Ganner, A., Cubitt, L., Brewer, R., Kim, D.-K., Kajba, C. M., Forrester, N., Dace, P., De Jonghe, J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01800-z · Cited by 62
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies
Haase, V. H. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.05.004 · Cited by 65
Polycythemia vera and other primary polycythemias
Prchal, J. T. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000154029.05396.d2 · Cited by 62
Self-citationA Review of Familial, Genetic, and Congenital Aspects of Primary Varicose Vein Disease
Anwar, M. A., Adesina-Georgiadis, K. N., Shalhoub, J., Lim, C. S., Gohel, M., & Davies, A. H. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.112.963439 · Cited by 62
Hypoxia. 5. Hypoxia and hematopoiesis
Yoon, D., Ponka, P., & Prchal, J. T. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00044.2011 · Cited by 63
Self-citationIdiopathic erythrocytosis: a disappearing entity
McMullin, M. F. (2009) · Hematology · doi:10.1182/asheducation-2009.1.629 · Cited by 56
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management
Gangat, N., Szuber, N., & Tefferi, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26920 · Cited by 61
Seeley, T. W., Sternlicht, M. D., Klaus, S. J., Neff, T. B., & Liu, D. Y. (2017) · Hypoxia · doi:10.2147/hp.s130526 · Cited by 54
Increased activation of the hypoxia-inducible factor pathway in varicose veins
Lim, C. S., Kiriakidis, S., Paleolog, E. M., & Davies, A. H. (2012) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.10.111 · Cited by 53
Cario, H. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0985-1 · Cited by 51
Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression
Gordeuk, V. R., Miasnikova, G. Y., Sergueeva, A. I., Niu, X., Nouraie, M., Okhotin, D. J., Polyakova, L. A., Ammosova, T., Nekhai, S., Ganz, T., et al. (2011) · Blood · doi:10.1182/blood-2011-03-345512 · Cited by 51
Self-citationOverview of Myeloproliferative Neoplasms
Tremblay, D. A., Yacoub, A., & Hoffman, R. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.12.001 · Cited by 52
The clinical and laboratory evaluation of the patient with erythrocytosis
Lee, G., & Arcasoy, M. O. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.03.007 · Cited by 48
Investigation and Management of Erythrocytosis
McMullin, M. F. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0334-1 · Cited by 49
Progress in detecting cell-surface protein receptors: the erythropoietin receptor example
Elliott, S., Sinclair, A. M., Collins, H., Rice, L. L., & JELKMANN, W. E. B. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1947-2 · Cited by 50
McClain, D. A., Abuelgasim, K. A., Nouraie, M. S., Salomón-Andonie, J., Niu, X., Miasnikova, G., Polyakova, L. A., Sergueeva, A., Okhotin, D. J., Cherqaoui, R., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0961-5 · Cited by 49
Self-citationGenetic basis of congenital erythrocytosis
Bento, C. (2018) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12828 · Cited by 52
Effects of Germline VHL Deficiency on Growth, Metabolism, and Mitochondria
Perrotta, S., Roberti, D., Bencivenga, D., Corsetto, P. A., O’Brien, K. A., Caiazza, M., Stampone, E., Allison, L., Fleck, R. A., Scianguetta, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1907362 · Cited by 45
Bond, J., Gale, D. P., Connor, T. M. F., Adams, S. P., de Boer, J., Gascoyne, D. M., Williams, O., Maxwell, P. H., & Ancliff, P. (2011) · Blood · doi:10.1182/blood-2010-12-327569 · Cited by 46
The von Hippel‐Lindau Tumor Suppressor Protein: An Update
Kaelin, W. G. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35019-2 · Cited by 45
Effects of VHL Deficiency on Endolymphatic Duct and Sac
Gläsker, S., Lonser, R. R., Tran, M. G. B., Ikejiri, B. L., Butman, J. A., Zeng, W., Maxwell, P. H., Zhuang, Z., Oldfield, E. H., & Vortmeyer, A. O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1104 · Cited by 45
Self-citation
Metadata
- Authors
- Gordeuk, V. R., Sergueeva, A. I., Miasnikova, G. Y., Okhotin, D., Voloshin, Y., Choyke, P. L., Butman, J. A., Jedlickova, K., Prchal, J. T., & Polyakova, L. A.
- Affiliations
- National Institutes of Health (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-05-15
- Volume
- 103
- Issue
- 10
- Pages
- 3924-3932
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1979891446
- Cited by
- 273
- References
- 43
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 18 · 2021: 13 · 2020: 10 · 2019: 10 · 2018: 9 · 2017: 9 · 2016: 15 · 2015: 13 · 2014: 6 · 2013: 14 · 2012: 15
- FWCI
- 11.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Digital Howard (Howard University) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL5007-09, UH1-HL03679-05, UH1HL003679, R01HL066333, R01HL66333-01)
- National Center for Research Resources (M01RR010284, M01-RR10284)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- Chuvash polycythemia, von Hippel-Lindau gene, hypoxia sensing, HIF-1α, erythropoietin, thrombosis, vertebral hemangioma, varicose veins, vascular endothelial growth factor, hypoxia adaptation, von Hippel-Lindau disease
- MeSH terms
- Adaptation, Physiological, Adolescent, Adult, Hypoxia, Child, Cross-Sectional Studies, Female, Homozygote, Humans, Male, Mutation, Neoplasms, Polycythemia, Retrospective Studies, Russia, Syndrome, Thrombosis, Transcription Factors, Vascular Diseases, Survival Rate, Tumor Suppressor Proteins, Vascular Endothelial Growth Factor A, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review